Clinical Trial Update: Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients [NA]

View source ↗

Summary

A clinical trial comparing intermediate-dose cyclophosphamide plus G-CSF with or without recombinant human thrombopoietin for mobilizing peripheral blood CD34+ …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Filgrastim (filgrastim)
• recombinant human thrombopoietin (recombinant human thrombopoietin)

Snippet

Sponsor: Wang Guorong | Conditions: Multiple Myeloma | NA | Status: UNKNOWN